Celecoxib, Irinotecan and Concurrent Radiotherapy in Preoperative Pancreatic Cancer
Status:
Terminated
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are to examine the effects of a new combination of drugs,
celecoxib (Celebrex®) and irinotecan (CPT-11), with standard radiation therapy on people
before they undergo surgery; to determine what effects this combination has on pancreatic
cancer; and to determine the highest dose of celecoxib and irinotecan that can be given
safely without causing severe side effects. While not an endpoint, it is hoped that this
combination will also shrink tumors enough for excision.